Literature DB >> 16094360

Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Michael T Hemann1, Anka Bric, Julie Teruya-Feldstein, Andreas Herbst, Jonas A Nilsson, Carlos Cordon-Cardo, John L Cleveland, William P Tansey, Scott W Lowe.   

Abstract

The c-Myc oncoprotein promotes proliferation and apoptosis, such that mutations that disable apoptotic programmes often cooperate with MYC during tumorigenesis. Here we report that two common mutant MYC alleles derived from human Burkitt's lymphoma uncouple proliferation from apoptosis and, as a result, are more effective than wild-type MYC at promoting B cell lymphomagenesis in mice. Mutant MYC proteins retain their ability to stimulate proliferation and activate p53, but are defective at promoting apoptosis due to a failure to induce the BH3-only protein Bim (a member of the B cell lymphoma 2 (Bcl2) family) and effectively inhibit Bcl2. Disruption of apoptosis through enforced expression of Bcl2, or loss of either Bim or p53 function, enables wild-type MYC to produce lymphomas as efficiently as mutant MYC. These data show how parallel apoptotic pathways act together to suppress MYC-induced transformation, and how mutant MYC proteins, by selectively disabling a p53-independent pathway, enable tumour cells to evade p53 action during lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16094360      PMCID: PMC4599579          DOI: 10.1038/nature03845

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  30 in total

1.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

2.  Induction of apoptosis in fibroblasts by c-myc protein.

Authors:  G I Evan; A H Wyllie; C S Gilbert; T D Littlewood; H Land; M Brooks; C M Waters; L Z Penn; D C Hancock
Journal:  Cell       Date:  1992-04-03       Impact factor: 41.582

Review 3.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

4.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

5.  Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.

Authors:  T H Rabbitts; P H Hamlyn; R Baer
Journal:  Nature       Date:  1983 Dec 22-1984 Jan 4       Impact factor: 49.962

6.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

7.  The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line.

Authors:  M Bemark; M S Neuberger
Journal:  Oncogene       Date:  2000-07-13       Impact factor: 9.867

8.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

9.  Mutations in the coding region of c-MYC in AIDS-associated and other aggressive lymphomas.

Authors:  H M Clark; T Yano; T Otsuki; E S Jaffe; D Shibata; M Raffeld
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

10.  Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.

Authors:  S E Salghetti; S Y Kim; W P Tansey
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

View more
  206 in total

1.  An Integrated Genetic-Genomic Approach for the Identification of Novel Cancer Loci in Mice Sensitized to c-Myc-Induced Apoptosis.

Authors:  Susan M Mendrysa; Keiko Akagi; Jean Roayaei; Wen-Hui Lien; Neal G Copeland; Nancy A Jenkins; Robert N Eisenman
Journal:  Genes Cancer       Date:  2010-05

Review 2.  c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.

Authors:  Chenguang Wang; Yanhong Tai; Michael P Lisanti; D Joshua Liao
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

Review 3.  BH3-only proteins in apoptosis at a glance.

Authors:  Lina Happo; Andreas Strasser; Suzanne Cory
Journal:  J Cell Sci       Date:  2012-03-01       Impact factor: 5.285

Review 4.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

Review 5.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

Review 6.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

7.  Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Authors:  Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.

Authors:  Karen Keeshan; Pauline Vieugué; Shahzya Chaudhury; Loveena Rishi; Coline Gaillard; Lu Liang; Elaine Garcia; Takuro Nakamura; Nader Omidvar; Scott C Kogan
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

Review 9.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

10.  miR-19 is a key oncogenic component of mir-17-92.

Authors:  Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.